Chronic Mechanical Circulatory Support for Inotrope-Dependent Heart Failure Patients Who Are Not Transplant Candidates

Rogers, Joseph G.; Butler, Javed; Lansman, Steven L.; Gass, Alan; Portner, Peer M.; Pasque, Michael K.; Pierson, Richard N.; Investigators, Intrepid Global Pilot Study

doi:10.1016/j.jacc.2007.03.063

Cited by 305 publications

(190 citation statements)

References 23 publications

Supporting

Mentioning

173

Contrasting

Unclassified

Order By: Relevance

“…8 Initial clinical trials of older pulsatile flow LVADs used as destination therapy demonstrated 1-year survival of 52%, 9 and more recent studies of continuous flow pumps, used for the same indication, showed 1-year survival of 73%. 10 These studies also documented improvements in functionality and quality of life relative to that seen with medicallytreated HF.…”

mentioning

confidence: 99%

Cost of Ventricular Assist Devices

2013

View full text Add to dashboard Cite

mentioning

confidence: 99%

Cost of Ventricular Assist Devices

2013

View full text Add to dashboard Cite

“…Specifically, the showed an 82% 1 year freedom from device malfunction [9]. A similar trial was undertaken with the Novacor™ system called INTrEPID (Investigation of Nontransplant-Eligible Patients Who Are Inotrope Dependent)-like REMATCH, LVAD survival was superior to optimal medical therapy at one year (27% vs 11%) [10] (Figure 1). …”

Section: The First Generation Implantable Lvadsmentioning

confidence: 98%

The Implantable Left Ventricular Assist Device: A Bridge to a Destination

Samuels¹

2013

J Clin Exp Cardiolog

View full text Add to dashboard Cite

The Implantable Left Ventricular Assist Device (LVAD) has been in clinical use for several decades, serving originally as a therapy for bridging patients to heart transplantation (BTT). For the past fifteen years, the implantable LVAD has also served as a permanent device in patients who are not eligible for cardiac transplantationDestination Therapy (DT). Although early results were markedly superior to optimal medical management (OMM), device durability was limited. In response, improvements in patient selection and pump design have translated into improved outcomes. As such, a broader acceptance of LVAD therapy for end-stage heart failure has been observed.

show abstract

“…A total of 85% of the LVAD-treated patients had minimal or no heart-failure symptoms. Five Novacor ® patients and one OMT patient improved sufficiently while on therapy to qualify for cardiac transplantation [15]. The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial have also demonstrated that implantation of the HeartMate XVE LVAD, as destination therapy, can provide survival superior to any known medical treatment in patients with end-stage heart failure who are ineligible for transplantation [16].…”

Section: Surgical Management Of Congestive Heart Failurementioning

confidence: 99%

“…Whereas the role for LVADs as a bridge-to-transplantation has been established, the data supporting their role as permanent therapy in nontransplant candidates is still limited. The Investigation of Nontransplant-Eligible Patients Who Are Inotrope Dependent (INTrEPID) trial was a prospective, nonrandomized clinical trial comparing LVAD with optimal medical therapy (OMT) [15]. A total of 55 patients with NYHA functional class IV symptoms who failed weaning from inotropic support were offered a Novacor LVAD.…”

mentioning

confidence: 99%